Department of Clinical Laboratory, Yantaishan Hospital, Yantai 264000, Shandong Province, China.
Department of Clinical Laboratory, The Affiliated Qingdao Central Hospital of Qingdao University, The Second Affiliated Hospital of Medical College of Qingdao University, Qingdao 266042, Shandong Province, China.
Comput Math Methods Med. 2022 Apr 28;2022:4217270. doi: 10.1155/2022/4217270. eCollection 2022.
Acute myocardial infarction (AMI) refers to the acute necrosis of part of the myocardium caused by persistent and severe myocardial ischemia. This study is aimed at investigating the efficacy of tirofiban combined with ticagrelor in AMI patients after percutaneous coronary intervention (PCI) and its effects on plasma activated partial thromboplastin time (APTT), fibrinogen (FIB), D-dimer (D-D) levels, myocardial injury markers, and inflammatory factors.
68 AMI patients with AMI who received PCI were divided into control group and observation group (n =34) according to postoperative treatment methods. Both groups received ticagrelor tablets (90 mg). The observation group was additionally given tirofiban (10 g/kg). APTT, FIB, D-D, serum myoglobin (MB), cardiac troponin I (cTnI), serum C-reactive protein (CRP), tumor necrosis factor- (TNF-), and IL-6, myeloperoxidase (MPO) levels and the peak time in both groups were detected. The incidence of cardiovascular events and drug safety were compared.
After treatment, APTT was increased, and FIB and D-D levels were decreased in both groups. After treatment, the APTT in the observation group was longer, and FIB and D-D levels were lower than those in the control group. The peak time of serum MB and cTnI in the observation group was earlier than that in the control group. The levels of serum MB and cTnI in the observation group were lower than those in the control group. After treatment, serum CRP, TNF-, IL-6, and MPO levels were decreased. And the incidence of cardiovascular events was reduced.
Tirofiban combined with ticagrelor can improve coagulation function, protect myocardium, relieve inflammation, and reduce the risk of cardiovascular events in patients with AMI after PCI.
急性心肌梗死（AMI）是指由于持续和严重的心肌缺血导致部分心肌的急性坏死。本研究旨在探讨替罗非班联合替格瑞洛在经皮冠状动脉介入治疗（PCI）后的 AMI 患者中的疗效及其对血浆活化部分凝血活酶时间（APTT）、纤维蛋白原（FIB）、D-二聚体（D-D）水平、心肌损伤标志物和炎症因子的影响。
根据术后治疗方法，将 68 例接受 PCI 的 AMI 患者分为对照组和观察组（n=34）。两组均给予替格瑞洛片（90mg）。观察组加用替罗非班（10μg/kg）。检测两组 APTT、FIB、D-D、血清肌红蛋白（MB）、心肌肌钙蛋白 I（cTnI）、血清 C 反应蛋白（CRP）、肿瘤坏死因子-（TNF-）、白细胞介素-6（IL-6）、髓过氧化物酶（MPO）水平及峰值时间，比较两组心血管事件发生率及药物安全性。
治疗后，两组 APTT 升高，FIB、D-D 水平降低；观察组治疗后 APTT 时间长于对照组，FIB、D-D 水平低于对照组；观察组血清 MB、cTnI 峰值时间早于对照组，血清 MB、cTnI 水平低于对照组；治疗后两组血清 CRP、TNF-、IL-6、MPO 水平降低，心血管事件发生率降低。
替罗非班联合替格瑞洛可改善 PCI 后 AMI 患者的凝血功能，保护心肌，减轻炎症反应，降低心血管事件风险。
